News
FSNUF
57.00
NaN%
--
Fresenius SE Non-GAAP EPS of €0.82, revenue of €5.74B; reaffirms FY26 outlook
Seeking Alpha · 05/06 07:28
DaVita tops chart as the only large-cap healthcare services name rated Strong Buy
Seeking Alpha · 03/09 15:24
Fresenius SE Co. KGaA reports FY results
Seeking Alpha · 02/25 10:15
DaVita: Some Success Is Possible, But Volatility Is Still Heavy
Seeking Alpha · 02/03 15:30
My Dividend Stock Portfolio: New November Dividend Record - 100 Holdings With 12 Buys
Seeking Alpha · 01/05 20:47
Fresenius SE& Co. misses Q3 estimates
Seeking Alpha · 11/05/2025 07:23
My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 13 Buys
Seeking Alpha · 10/09/2025 14:00
Weekly Report: what happened at FSNUF last week (0908-0912)?
Weekly Report · 09/15/2025 11:44
Weekly Report: what happened at FSNUF last week (0901-0905)?
Weekly Report · 09/08/2025 11:47
Weekly Report: what happened at FSNUF last week (0825-0829)?
Weekly Report · 09/01/2025 11:40
Weekly Report: what happened at FSNUF last week (0818-0822)?
Weekly Report · 08/25/2025 11:54
More
Webull provides a variety of real-time FSNUF stock news. You can receive the latest news about Fresenius through multiple platforms. This information may help you make smarter investment decisions.
About FSNUF
Fresenius SE & Co. KGaA is a Germany-based healthcare group focused on products and services for the treatment of critically and chronically ill patients. The Company operates through its core businesses, Fresenius Kabi and Fresenius Helios. Fresenius Kabi develops and supplies biopharmaceuticals, clinical nutrition products, medical technologies, intravenously administered generic drugs, and infusion therapies. Fresenius Helios is Europe’s private healthcare provider, operating hospitals, outpatient centers, and other healthcare facilities in Germany, Spain, and Latin America. Fresenius also holds an investment in Fresenius Medical Care, a provider of dialysis products and services for patients with chronic kidney disease.